What is 'Orphan Drug Credit'

The orphan drug credit is a federal tax credit available to businesses, not individuals, that gives pharmaceutical companies incentives to develop medications and treatments for rare diseases that do not affect enough people for the company to be able to make a profit on the sales of those treatments to the patient population.

BREAKING DOWN 'Orphan Drug Credit'

The orphan drug credit is a credit available to pharmaceutical companies to create financial incentives to develop medications and treatments for rare diseases that affect small populations. This credit can be claimed by the pharmaceutical company whether testing to develop the treatments is performed by the company itself or contracted out to third parties. With some exceptions, testing must occur in the United States. Orphan drugs are drugs developed to treat orphan diseases, which is the group term for extremely rare medical conditions such as Huntington's Disease, ALS and Tourette Syndrome. 

Despite being rare conditions individually, orphan diseases affect a large number of people. Although there are almost 30 million people suffering from orphan diseases in the United States, there are only approved treatments for four percent of those diseases. This means that patients with 96 percent of orphan diseases have no good treatment options. The orphan drug tax credit is an effort to encourage the development of treatments for these diseases to give relief to the patients affected by them. Without these tax credits, pharmaceutical companies would be forced to charge prices for the treatments that are so high that the affected patients could never afford them, which would defeat the purpose of developing these treatments in the first place. The orphan drug tax credit bridges this gap and helps the companies develop the treatments while allowing them to be reasonably-enough priced that the people who need them can afford them.

History of Orphan Drug Credit

Before the Orphan Drug Act was passed in 1983, pharmaceutical companies and medical researchers were unable and unwilling to invest in treatments for extremely rare diseases, because they knew developing these treatments would never pay for themselves. There simply aren't enough patients of each orphan disease to be able to recoup their expenses, let along make a profit. Clinical trials cost thousands of dollars per patient even when the researchers could find enough patients to run these trials. They were unable to develop these treatments without a sponsor for the treatment development process, and many treatments sat waiting for a sponsor.

Between 1983 and 2018, the orphan drug tax credit gave a credit of 50 percent of the clinical testing costs for drugs being tested under section 505(i) of the Federal Food, Drug and Cosmetic Act. Part of the overhaul of the tax code conducted in 2017 during the Trump administration reduced the amount of the orphan drug tax credit from 50 percent to 25 percent of qualified clinical testing expenses beginning in 2018. This was seen as harmful by the National Organization for Rare Disorders and many other advocacy groups.

RELATED TERMS
  1. New Drug

    New drug is an original or innovative medication or therapy that ...
  2. Phase 4

    Phase 4 refers to the final stage of new drug testing, which ...
  3. Informed Consent

    Informed consent is permission from a medical patient to a doctor ...
  4. Phase 2

    Phase 2 is the second phase of clinical trials for an experimental ...
  5. Orange Book

    The Orange Book is a list of drugs that the U.S. Food and Drug ...
  6. New Drug Application (NDA)

    The New Drug Application (NDA) is the formal final step taken ...
Related Articles
  1. Investing

    3 of America's Most Expensive Drugs and Who Profits From Them

    Learn about orphan drugs that are some of the most expensive drugs in America. Read about the companies that manufacture these drugs.
  2. Investing

    Opko Gets Orphan Status for Genetic Disorder Drug

    Opko’s neurological disorder drug CUR-1916 qualifies for many benefits under orphan drug status.
  3. Personal Finance

    Supplemental Indications: The Promising Pharma Stream (GILD)

    While supplemental indications can lead to more revenues and wider treatment options, they may add substantially to the drug cost for the end patients.
  4. Investing

    It's No Accident That Drugs Are Expensive

    Branded drugs are expensive in large part because it's expensive and risky to develop them
  5. Personal Finance

    What to Do With Orphaned Investment Accounts

    If your investment accounts end up being orphaned for one of many possible reasons, take one of these actions.
  6. Investing

    Pharma Balks at German Price Control (BAYRY, RHHBY)

    Drug makers are worried about a proposed new German law that would tighten price controls on prescription drugs.
  7. Investing

    AstraZeneca’s Lung Cancer Duo Flops

    AstraZeneca’s combo of the experimental drug tremelimumab and Imfinzi failed to slow disease progression or extend life for lung cancer patients
  8. Insurance

    Big Pharma: Will Price Pressure Happen No Matter What?

    Watch out for a possible decline in pharmaceutical stock prices, thanks to a renewed debate about the role of government policy and macroeconomic headwinds.
  9. Investing

    Investing In The Biotech Sector

    The biotech sector is more than just medical research. Read this before you invest.
RELATED FAQS
  1. Can your insurance company drug test you?

    Learn why insurance companies conduct drug tests and how a lifestyle free of drugs can save you big money on health and life ... Read Answer >>
  2. Do financial advisors get drug tested?

    Financial advisor regulatory bodies do not require drug testing, but many individual firms that hire advisors do. Read Answer >>
  3. What debt/equity ratio is common for companies in the drugs sector?

    Find out more about the drugs sector, what the debt-to-equity ratio measures and what debt-to-equity ratio is common for ... Read Answer >>
Trading Center